MYLAN-BUDESONIDE AQ 64 MCG
BUDESONIDE : 64 MCG · DIN 02241003 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is MYLAN-BUDESONIDE AQ?
MYLAN-BUDESONIDE AQ 64 MCG contains BUDESONIDE : 64 MCG. It is listed in the Health Canada Drug Product Database under DIN 02241003, held by MYLAN PHARMACEUTICALS ULC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as marketed, status dated 21-Apr-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYLAN-BUDESONIDE AQ used for?
MYLAN-BUDESONIDE AQ (Budesonide Aqueous Nasal Spray) is indicated for the treatment of seasonal allergic and allergic/non-allergic perennial and vasomotor rhinitis unresponsive to conventional therapy in patients 6 years and older, and for the treatment of nasal polyps and in the prevention of nasal polyps after polypectomy in patients 12 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is MYLAN-BUDESONIDE AQ called?
The same molecule, BUDESONIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DuoResp Spiromax | Latin | Australia, Czechia |
| Pulmicort Turbuhaler | Latin | Australia, Bahrain, Czechia, Morocco |
| SYMBICORT TURBUHALER | Latin | Bahrain, Czechia, Saudi Arabia |
| BUFOMIX EASYHALER | Latin | Bahrain, Czechia |
| Jorveza | Latin | Australia, Czechia |
| Budenofalk | Latin | Australia, Czechia |
| GIONA EASYHALER | Latin | Czechia |
| PULMICORT | Latin | Bahrain, Czechia, Morocco |
| Pulmicort Respules | Latin | Australia |
| Pulmistad | Latin | Bahrain, Saudi Arabia |
| Breztri Aerosphere | Latin | Australia, South Africa |
| BUDENA | Latin | Morocco |
| Entocort | Latin | Australia, Bahrain, Czechia |
| AIRBUFO FORSPIRO | Latin | Czechia |
| BUDECORT | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02241003 |
|---|---|
| Brand name | MYLAN-BUDESONIDE AQ |
| Generic / active ingredient | BUDESONIDE : 64 MCG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 64 MCG |
| Dosage form | SPRAY, METERED DOSE |
| Route of administration | NASAL |
| Schedule | Prescription |
| ATC code | R01AD05 BUDESONIDE |
| AHFS class | 52:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Apr-2011 |
| Original market date | 1999-11-23 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02241003 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2241003 |
| Brand name | MYLAN-BUDESONIDE AQ |
| Active ingredient / INN | BUDESONIDE : 64 MCG |
| ATC code | R01AD05 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R01 |
| AHFS class | 52:08.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | MYLAN PHARMACEUTICALS ULC |
How is it stored and handled?
null
How is it supplied?
Amber glass bottles of 120 doses
Which pack is which?
| Strength on the label | 64 MCG |
|---|---|
| Dosage form | SPRAY, METERED DOSE |
| Route | NASAL |
| Packaging as described in the monograph | Amber glass bottles of 120 doses |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code R01AD05 BUDESONIDE. 3 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-BUDESONIDE AQ | 100 MCG | SPRAY, METERED DOSE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02230648 |
| RHINOCORT AQUA | 64 MCG | SPRAY, METERED DOSE | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02231923 |
| RHINOCORT AQUA 100MCG | 100 MCG | METERED-DOSE AEROSOL | ASTRA PHARMA INC. | CANCELLED POST MARKET | DIN 01974432 |
| RHINOCORT TURBUHALER 100 MCG/DOSE | 100 MCG | POWDER | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | DIN 02035324 |
Who else supplies BUDESONIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUDESONIDE appears in 1002 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BUDESONIDE cost around the world?
BUDESONIDE is listed on 13 national price registers Nexara tracks, across 420 pack listings published on 12 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 20 | 81 | 08 Sep 2026 |
| Greece | producer price (ex-factory) | 68 | 68 | 03 Sep 2026 |
| South Africa | single exit price | 37 | 42 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 17 | 39 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 39 | 39 | 02 Sep 2026 |
| United States | acquisition | 5 | 35 | 03 Sep 2026 |
| Saudi Arabia | public | 30 | 31 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 22 | 25 | 03 Sep 2026 |
| Luxembourg | reimbursement | 19 | 19 | 05 Sep 2026 |
| United Arab Emirates | public | 16 | 16 | 31 Aug 2026 |
| Bahrain | retail (max) | 10 | 16 | 01 Sep 2026 |
| Morocco | PPV (public price) | 5 | 7 | 05 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.